Please login to the form below

Not currently logged in
Email:
Password:

CROS NT appoints Andrew MacGarvey to lead new UK office

Contract research organisation's new facility will be based in Milton Keynes

CROS NT Andrew MacGarveyItalian contract research organisation CROS NT has expanded into the UK and appointed Andrew MacGarvey to lead operations from its new facility in Milton Keynes.

MacGarvey has over 15 years' experience within the pharmaceutical sector and as CROS NT's new vice president of UK and USA operations he will be tasked with growing ties with the contract research organisation's UK-based customers.

MacGarvey previously held senior management and director roles at multiple contract research organisation (CROs) in Europe and the US.

"I have followed the activities of CROS NT for some time," MacGarvey said. "I am excited by the opportunity to help with the growth of the business. CROS NT are focused on customer care, something that is very important to me. I will be bringing their great service to the UK and ultimately the US."

Verona-headquartered CROS NT's new UK base joins its existing facilities in Italy and Augsburg, Germany.

17th August 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics